Ardelyx (ARDX) Aktievy
Ardelyx, Inc. upptäcker, utvecklar och marknadsför läkemedel för att behandla medicinska behov i USA och internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 6/6 |
| Framtida tillväxt | 6/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 4/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
Inga risker upptäckta för ARDX från våra riskkontroller.
ARDX Community Fair Values
Create NarrativeSee what 122 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Ardelyx, Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$6.23 |
| 52 veckors högsta | US$8.40 |
| 52 veckors lägsta | US$3.49 |
| Beta | 0.61 |
| 1 månads förändring | -3.41% |
| 3 månaders förändring | -7.84% |
| 1 års förändring | 53.45% |
| 3 års förändring | 75.00% |
| 5 års förändring | -10.23% |
| Förändring sedan börsintroduktionen | -55.85% |
Senaste nyheter och uppdateringar
Seeking Alpha • May 08
Ardelyx: Low Price, But High Implied Valuation
Summary Ardelyx (ARDX) is rated Buy, driven by robust commercial execution of IBSRELA and XPHOZAH, and management's $1B revenue target by FY2029. ARDX's ACCEL Phase III trial offers significant upside optionality, potentially tripling IBSRELA's addressable market if successful. DCF analysis yields a base-case share price of $24.27, well above current levels, even excluding ACCEL trial upside. Options market sentiment is strongly bullish (P/C ratio 0.07), reflecting investor confidence in near-term upside following solid earnings momentum. Read the full article on Seeking Alpha
Uppdatering av berättelse • May 05
ARDX: Extended 2042 Patent Protection Will Support Longer-Term Upside Potential
Analysts have nudged their average price target for Ardelyx higher to about $16.33 from $16.10, citing recent patent news that extends protection to November 2042 as a key support for this updated view. Analyst Commentary Bullish Takeaways Bullish analysts highlight the new patent protection to November 2042 as a key support for their higher valuation ranges, arguing that a longer exclusivity window can support the commercial life of Ardelyx's products.Analysartikel • May 04
Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
It's been a pretty great week for Ardelyx, Inc. ( NASDAQ:ARDX ) shareholders, with its shares surging 15% to US$6.88 in...
Uppdatering av berättelse • Apr 21
ARDX: Extended 2042 Patent Horizon Will Support Multiyear Revenue Roadmap
The analyst fair value estimate for Ardelyx has increased from $10.00 to $13.00, supported by recent price target revisions and analyst views that the new patent extending to November 2042 strengthens the company’s long-term profile. Analyst Commentary Recent research commentary around Ardelyx centers on the updated patent timeline to November 2042 and how that may influence valuation assumptions.Recent updates
Seeking Alpha • May 08
Ardelyx: Low Price, But High Implied Valuation
Summary Ardelyx (ARDX) is rated Buy, driven by robust commercial execution of IBSRELA and XPHOZAH, and management's $1B revenue target by FY2029. ARDX's ACCEL Phase III trial offers significant upside optionality, potentially tripling IBSRELA's addressable market if successful. DCF analysis yields a base-case share price of $24.27, well above current levels, even excluding ACCEL trial upside. Options market sentiment is strongly bullish (P/C ratio 0.07), reflecting investor confidence in near-term upside following solid earnings momentum. Read the full article on Seeking AlphaUppdatering av berättelse • May 05
ARDX: Extended 2042 Patent Protection Will Support Longer-Term Upside Potential
Analysts have nudged their average price target for Ardelyx higher to about $16.33 from $16.10, citing recent patent news that extends protection to November 2042 as a key support for this updated view. Analyst Commentary Bullish Takeaways Bullish analysts highlight the new patent protection to November 2042 as a key support for their higher valuation ranges, arguing that a longer exclusivity window can support the commercial life of Ardelyx's products.Analysartikel • May 04
Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
It's been a pretty great week for Ardelyx, Inc. ( NASDAQ:ARDX ) shareholders, with its shares surging 15% to US$6.88 in...Uppdatering av berättelse • Apr 21
ARDX: Extended 2042 Patent Horizon Will Support Multiyear Revenue Roadmap
The analyst fair value estimate for Ardelyx has increased from $10.00 to $13.00, supported by recent price target revisions and analyst views that the new patent extending to November 2042 strengthens the company’s long-term profile. Analyst Commentary Recent research commentary around Ardelyx centers on the updated patent timeline to November 2042 and how that may influence valuation assumptions.
Uppdatering av berättelse • Apr 06
ARDX: Extended Patent Runway And 2029 Revenue Guidance Will Support Repricing
Ardelyx's consensus analyst price target has moved higher toward $19, with the shift largely tied to stronger Ibsrela revenue guidance, extended patent protection into the 2040s, and analyst expectations reflected in updated P/E, growth, and margin assumptions. Analyst Commentary Bullish analysts have been revising their views higher, with a series of price target increases and rating upgrades clustering around Ardelyx's updated Ibsrela guidance and extended patent protection.Uppdatering av berättelse • Mar 23
ARDX: Extended Patent Life And IBS Guidance Are Expected To Unlock Upside
The analyst fair value estimate for Ardelyx has been raised from $13.50 to $16.10. Analysts point to higher Ibsrela revenue guidance, extended intellectual property protection into the 2040s, and a series of upward revisions to Street price targets as key drivers of the change.Uppdatering av berättelse • Mar 09
ARDX: Extended Patent Runway And 2029 Revenue Outlook Will Drive Bullish Repricing
Ardelyx's analyst price target has moved higher, with several firms lifting their views into a $14 to $19 range. Analysts highlight extended patent protection on key assets, updated Ibsrela revenue guidance that includes targets of $410m to $430m in FY26 and $1b by 2029, and a stronger outlook for the broader product portfolio and cash position.Uppdatering av berättelse • Feb 22
ARDX: Extended Patent Runway And 2029 Revenue Path Will Support Bullish Outlook
The analyst fair value estimate for Ardelyx has shifted from $16.00 to $19.00, as analysts factor in higher projected revenue, updated profitability assumptions, and extended intellectual property protection highlighted in recent research notes. Analyst Commentary Recent Street research on Ardelyx has leaned firmly positive, with several bullish analysts lifting price targets and, in some cases, upgrading their ratings after management updates and new patent developments.Uppdatering av berättelse • Feb 08
ARDX: Multiyear Revenue Roadmap And CIC Expansion Will Drive Upside
Analysts lifted their fair value estimate for Ardelyx to $10.00 from $8.00, citing updated Street research that highlights stronger Ibsrela revenue guidance toward $410m to $430m by FY26 and a US$1b annual revenue outlook by 2029, along with pipeline progress and a solid cash position. Analyst Commentary Recent Street research has centered on Ibsrela guidance of US$410m to US$430m in FY26 and the long term US$1b annual revenue outlook for 2029, with several firms adjusting price targets and ratings to reflect those inputs, as well as updates on Xphozah, the broader pipeline, and the cash position.Uppdatering av berättelse • Jan 24
ARDX: Faster Path To 1b Revenue Is Expected To Unlock Upside
We are raising our Ardelyx fair value estimate from $12.30 to $13.50 as analysts point to higher Ibsrela revenue expectations, a faster ramp to the company’s $1b annual revenue goal, and updated guidance that supports stronger margins and a lower forward P/E multiple. Analyst Commentary Recent Street research is broadly constructive on Ardelyx, with multiple firms lifting price targets after the latest Ibsrela revenue outlook and guidance update.Analysartikel • Jan 21
Ardelyx, Inc. (NASDAQ:ARDX) Stock Catapults 37% Though Its Price And Business Still Lag The Industry
Ardelyx, Inc. ( NASDAQ:ARDX ) shares have continued their recent momentum with a 37% gain in the last month alone. The...Uppdatering av berättelse • Jan 09
ARDX: Higher Revenue Guidance Is Expected To Support Long Term Upside
Narrative Update on Ardelyx The analyst price target for Ardelyx has shifted higher, with our fair value estimate moving from US$11.60 to US$12.30 as analysts factor in stronger Ibsrela revenue guidance and updated Street targets of up to US$19. Analyst Commentary Recent Street research on Ardelyx has focused heavily on updated Ibsrela revenue guidance and how that might influence the company’s valuation and execution priorities over the next several years.Uppdatering av berättelse • Dec 25
ARDX: Long-Term Profitability Improvements Will Drive Stronger Bullish Outlook
Analysts have raised their price target on Ardelyx from 15 dollars to 16 dollars. This reflects slightly stronger expectations for long term revenue growth, improved profitability, and a modestly lower future earnings multiple despite a higher discount rate.Uppdatering av berättelse • Dec 11
ARDX: Upcoming Leadership Transition Will Support Long Term Earnings Upside
Analysts have modestly reiterated their confidence in Ardelyx, keeping the price target essentially unchanged at approximately 11.60 dollars per share. Minor adjustments to the discount rate and valuation inputs did not materially alter their long term earnings and growth outlook for the company.Uppdatering av berättelse • Nov 26
ARDX: Commercial Execution Will Drive Shares Higher Under New Leadership
Ardelyx’s analyst price target has been raised from $12 to $14, a $2 increase. Analysts cite stronger commercial execution and discounted valuation under new management as key drivers for the higher outlook.Uppdatering av berättelse • Nov 07
ARDX: Ongoing Commercial Execution Will Unlock Upside From Discounted Levels
Analysts have raised Ardelyx’s fair value estimate from $11.36 to $11.73, citing stronger commercial execution, increased revenue growth potential, and a more favorable profit margin outlook. Analyst Commentary Recent coverage initiations have highlighted key perspectives among market observers evaluating Ardelyx’s trajectory and valuation.Analysartikel • Nov 02
Analyst Estimates: Here's What Brokers Think Of Ardelyx, Inc. (NASDAQ:ARDX) After Its Third-Quarter Report
The investors in Ardelyx, Inc. 's ( NASDAQ:ARDX ) will be rubbing their hands together with glee today, after the share...Analysartikel • Oct 11
Ardelyx, Inc. (NASDAQ:ARDX) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
The Ardelyx, Inc. ( NASDAQ:ARDX ) share price has softened a substantial 26% over the previous 30 days, handing back...Analysartikel • Jul 11
There's No Escaping Ardelyx, Inc.'s (NASDAQ:ARDX) Muted Revenues Despite A 26% Share Price Rise
Ardelyx, Inc. ( NASDAQ:ARDX ) shareholders would be excited to see that the share price has had a great month, posting...Analysartikel • May 15
Benign Growth For Ardelyx, Inc. (NASDAQ:ARDX) Underpins Stock's 28% Plummet
To the annoyance of some shareholders, Ardelyx, Inc. ( NASDAQ:ARDX ) shares are down a considerable 28% in the last...
Ny berättelse • Apr 27
Omnichannel Investments And Sales Teams Will Create Future IBSRELA Demand
Strategic investments and an expanded sales team are expected to drive demand for IBSRELA, boosting revenue and market share.Seeking Alpha • Feb 24
Ardelyx: Limited Pipeline, Rising Costs, And Uncertain Growth Ahead (Downgrade)
Summary Ardelyx, Inc. faces significant challenges in 2025 due to Xphozah's reimbursement issues and modest growth from Ibsrela, prompting a downgrade to "sell" and "market underperform." Xphozah's inclusion in a bundled system and loss of Medicare Part D coverage limits revenue potential, despite the company's $750 million annual sales guidance. Increased SG&A expenses and looming debt obligations raise concerns about Ardelyx's ability to achieve consistent profitability and fund necessary R&D investments. ARDX has strong liquidity with a current ratio over 2, but cash-generating capability and limited pipeline cast doubt on sustaining a $1 billion-plus market valuation. Read the full article on Seeking AlphaAnalysartikel • Feb 17
There's No Escaping Ardelyx, Inc.'s (NASDAQ:ARDX) Muted Revenues
Ardelyx, Inc.'s ( NASDAQ:ARDX ) price-to-sales (or "P/S") ratio of 5.4x might make it look like a strong buy right now...Seeking Alpha • Dec 20
Ardelyx: A Small Bet Its Latest Setback Will Be Temporary
Summary Ardelyx's stock has fallen substantially after a court dismissed its lawsuit against the CMS, impacting Xphozah's profitability due to Medicare bundling changes starting January 2025. Ardelyx's tenapanor franchise, including Ibsrela and Xphozah, shows strong sales growth, but Xphozah's future is uncertain without Medicare Part D coverage. Management's gamble to avoid TDAPA and provide Xphozah for free to Medicare patients impacts profitability, but analysts remain optimistic with numerous Buy ratings. The stock now is trading at just over three times FY24 sales net of cash, presenting a 'speculative buy' opportunity. Read the full article on Seeking AlphaSeeking Alpha • Nov 24
Ardelyx Lost The Lawsuit, But The Kidney PATIENT Act Will Save It
Summary Ardelyx lost a lawsuit against Medicare, impacting XPHOZAH's revenue potential, with no other major prospects in its pipeline. CMS's decision to move XPHOZAH to the bundled payment system significantly reduces its revenue, forcing Ardelyx to negotiate complex reimbursements. The Kidney PATIENT Act, if passed, will delay the inclusion of oral-only ESRD drugs in the bundled payment system, benefiting Ardelyx until 2027. Despite the lawsuit loss, bipartisan support for the Kidney PATIENT Act offers hope for Ardelyx's financial stability and tenapanor's coverage. Read the full article on Seeking AlphaSeeking Alpha • Nov 14
Ardelyx's Medicare Setback Casts Doubt On Long-Term Viability
Summary Ardelyx’s Q3 revenue grew to $98 million, with strong Xphozah sales despite CMS’s recent bundling ruling impacting future reimbursement. The CMS lawsuit dismissal affected Xphozah’s reimbursement prospects, creating significant regulatory uncertainty and limiting Ardelyx’s revenue control. Ibsrela faces substantial competition in the IBS-C market, with lofty revenue projections likely overstating its realistic market share. Ardelyx’s cash runway is around three years, bolstered by a $49.7 million loan, but rising SG&A expenses pose a long-term risk. I recommend a cautious hold for Ardelyx due to regulatory headwinds, competitive pressures, and uncertain long-term growth beyond tenapanor. Read the full article on Seeking AlphaAnalysartikel • Nov 03
Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Investors in Ardelyx, Inc. ( NASDAQ:ARDX ) had a good week, as its shares rose 5.5% to close at US$6.09 following the...Analysartikel • Oct 24
Ardelyx, Inc.'s (NASDAQ:ARDX) Shares Lagging The Industry But So Is The Business
With a price-to-sales (or "P/S") ratio of 6.3x Ardelyx, Inc. ( NASDAQ:ARDX ) may be sending very bullish signals at the...Analysartikel • Aug 25
Is Ardelyx (NASDAQ:ARDX) Weighed On By Its Debt Load?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysartikel • Aug 07
Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts
Ardelyx, Inc. ( NASDAQ:ARDX ) shareholders will have a reason to smile today, with the analysts making substantial...Seeking Alpha • Aug 05
Ardelyx Faces Rising Challenges Despite Revenue Growth
Summary Ardelyx's Q2 2024 revenues increased significantly to $73.2 million from $22.3 million in Q2 2023. SG&A expenses rose to $64.7 million in Q2 2024 due to commercialization efforts for Ibsrela and Xphozah. Despite revenue growth, Ardelyx reported a net loss of $16.5 million in Q2 2024, similar to Q2 2023. Xphozah revenue growth is impressive, but challenges with reimbursement may impact future revenues. ARDX remains a "hold" with increased caution due to reimbursement challenges, ongoing operating losses, and competitive pressures. Read the full article on Seeking AlphaAnalysartikel • Aug 04
Earnings Beat: Ardelyx, Inc. (NASDAQ:ARDX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Ardelyx, Inc. ( NASDAQ:ARDX ) just released its latest second-quarter results and things are looking bullish. The...Seeking Alpha • Jul 13
Ardelyx: Increased Focus On Ibsrela Due To Xphozah's Uncertain Outlook
Summary Ardelyx declined last week after the company said it will not apply for TDAPA with the CMS for Xphozah to be included in the bundle in 2025. Legislative efforts may provide temporary relief for Xphozah, but its long-term future remains uncertain. The uncertainty around Xphozah put more pressure on Ibsrela to perform in the IBS-C market. Ardelyx can deliver long-term shareholder value based on Ibsrela alone and Xphozah offers significant upside optionality. Read the full article on Seeking AlphaAnalysartikel • Jul 05
Why Investors Shouldn't Be Surprised By Ardelyx, Inc.'s (NASDAQ:ARDX) 25% Share Price Plunge
The Ardelyx, Inc. ( NASDAQ:ARDX ) share price has fared very poorly over the last month, falling by a substantial 25...Seeking Alpha • May 10
Ardelyx: Strong Execution, Fairly Valued
Summary Ardelyx has seen a substantial increase in its stock price since late 2022, when we last profiled the company, and Ardelyx recently posted better-than-expected quarterly results. The company has done a good job managing the launch of its flagship drug tenapanor, which is now approved for two indications. Ardelyx is posting impressive sales growth and is projected to be profitable in FY2025. An updated analysis around Ardelyx follows in the paragraphs below. Read the full article on Seeking AlphaAnalysartikel • May 04
Ardelyx, Inc. (NASDAQ:ARDX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Ardelyx, Inc. ( NASDAQ:ARDX ) defied analyst predictions to release its first-quarter results, which were ahead of...Seeking Alpha • May 03
Ardelyx Stock: A Crowded Market Curbs The Enthusiasm (Rating Downgrade)
Summary Since my previous review, Ardelyx stock has risen over 100%, driven by promising developments in its drug portfolio. Ardelyx raised U.S. revenue forecasts for Ibsrela in IBS-C to $1 billion, targeting about 10% of the market. Q1 earnings showed strong revenue growth but were offset by doubled SG&A expenses, maintaining a net loss. Downgrading ARDX stock to "Hold" due to the current valuation fully reflecting tenapanor's potential, despite financial and operational risks. Read the full article on Seeking AlphaAnalysartikel • Apr 17
Ardelyx, Inc.'s (NASDAQ:ARDX) Popularity With Investors Is Under Threat From Overpricing
It's not a stretch to say that Ardelyx, Inc.'s ( NASDAQ:ARDX ) price-to-sales (or "P/S") ratio of 12.7x right now seems...Seeking Alpha • Mar 13
Ardelyx Shrugs Off 'Mixed' Q4 Earnings
Summary Shares tanked 16% within the first 18 minutes of the press release, and dipped even lower in pre-market trading. Market sentiment was countered by bullish stances from at least four firms. Yet Wall Street continues to be oblivious, with only one of them mentioning XPHOZAH revenue contributions. UpToDate, the leading clinical decision tool for most doctors, supports the use of XPHOZAH. The nation’s top insurer, cost-conscious Kaiser Permanente, is spearheading the charge to provide broad access for XPHOZAH. In recent, near-unanimous positive vote for H.R. 5074, many members of Congress back the continuation of Medicare coverage for XPHOZAH. Read the full article on Seeking AlphaAnalysartikel • Feb 24
Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Shareholders might have noticed that Ardelyx, Inc. ( NASDAQ:ARDX ) filed its full-year result this time last week. The...Seeking Alpha • Feb 20
Ardelyx Q4 Preview: Recent Bull Run May Pause While Market Digests 2024 Guidance
Summary Ardelyx, Inc. shares have seen significant growth, up by 47% year-to-date and over 250% on a 5-year basis. The company markets and sells tenapanor, a drug approved for the treatment of Irritable Bowel Syndrome with constipation (IBS-C) and Chronic Kidney Disease, or CKD. Ardelyx recently shared expectations for "blockbuster" sales from Ibsrela in IBS-C, and $140-$150m revenues in 2024. If Ibsrela is set to become a blockbuster, it seems likely Xphozah will achieve the same in CKD - management will set revenue expectations for 2024 when earnings are announced Thursday. Given the recent bull run on shares - up >200% across the past year - I am assigning a "hold" recommendation, but after many years of struggle, management finally has its approval in CKD and it is not hard to see how Ardelyx could become a >$3-$5bn market cap company in time. Read the full article on Seeking AlphaSeeking Alpha • Jan 31
Ardelyx's XPHOZAH Still An Afterthought To The Pros
Summary Analysts are impressed by Ibsrela but still on the fence with Xphozah. Xphozah has shown up early on several top health plan formularies. After this month's preview, Wall Street may get Q4 earnings right but deeply underestimate 2024. Read the full article on Seeking AlphaSeeking Alpha • Jan 10
Ardelyx: FDA Approval For Xphozah Grants Further Sales Enhancement
Summary Ardelyx received FDA approval of its drug XPHOZAH for the treatment of hyperphosphatemia in patients with CKD after overcoming several regulatory hurdles. U.S. net product revenues of XPHOZAH, for the first quarter of its commercialization, are expected to be $2.5 million. Peak Sales of IBSRELA, approved for the treatment of patients with irritable bowel syndrome with constipation, has been guided higher to $1 billion. XPHOZAH has the ability to do well on the market because it can be given alongside phosphate binders; It is not a phosphate binder itself or a phosphate absorption inhibitor. Read the full article on Seeking AlphaAktieägarnas avkastning
| ARDX | US Biotechs | US Marknad | |
|---|---|---|---|
| 7D | -5.7% | -1.8% | -0.3% |
| 1Y | 53.4% | 32.7% | 24.1% |
Avkastning vs industri: ARDX översteg US Biotechs branschen som gav 32.7 % under det senaste året.
Avkastning vs Marknaden: ARDX översteg US marknaden som gav 24.1 % under det senaste året.
Prisvolatilitet
| ARDX volatility | |
|---|---|
| ARDX Average Weekly Movement | 9.0% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stabil aktiekurs: ARDX har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: ARDX s veckovolatilitet ( 9% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2007 | 489 | Mike Raab | www.ardelyx.com |
Ardelyx, Inc. upptäcker, utvecklar och kommersialiserar läkemedel för att behandla ouppfyllda medicinska behov i USA och internationellt. Företaget erbjuder IBSRELA, en minimalt absorberad småmolekylär terapi för behandling av patienter med irritabelt tarmsyndrom med förstoppning; och XPHOZAH, en fosfatabsorptionshämmare för att minska serumfosfor hos vuxna med kronisk njursjukdom som genomgår dialys. Ardelyx, Inc. var tidigare känt under namnet Nteryx, Inc. och bytte namn till Ardelyx, Inc. i juni 2008.
Ardelyx, Inc. Sammanfattning av grunderna
| ARDX grundläggande statistik | |
|---|---|
| Börsvärde | US$1.54b |
| Vinst(TTM) | -US$58.06m |
| Intäkter(TTM) | US$427.68m |
3.6x
P/S-förhållande-26.5x
P/E-förhållandeÄr ARDX övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| ARDX resultaträkning (TTM) | |
|---|---|
| Intäkter | US$427.68m |
| Kostnad för intäkter | US$108.82m |
| Bruttovinst | US$318.86m |
| Övriga kostnader | US$376.92m |
| Intäkter | -US$58.06m |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | -0.24 |
| Bruttomarginal | 74.56% |
| Nettovinstmarginal | -13.58% |
| Skuld/egenkapitalförhållande | 154.3% |
Hur har ARDX utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/18 15:21 |
| Aktiekurs vid dagens slut | 2026/05/15 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Ardelyx, Inc. bevakas av 18 analytiker. 10 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Julian Harrison | BTIG |
| Prakhar Agrawal | Cantor Fitzgerald & Co. |
| Yigal Nochomovitz | Citigroup Inc |